

## Abstract 178

### BILATERAL BROLUCIZUMAB INTRAVITREAL INJECTIONS IN AMD PATIENTS: A BRIEF REPORT

Oral

Vitiello L.\*, Abbinante G., Coppola A., Salerno G., Gagliardi V., Pellegrino A.

*Eye Unit, "Luigi Curto" Hospital, Polla, ASL Salerno, Salerno, Italy ~ Polla ~ Italy*

#### **Purpose:**

Brolucizumab is a latest-generation drug approved for age-related macular degeneration (AMD) treatment. Several studies have demonstrated its efficacy, but there is still little evidence on its safety in bilateral treatment. The purpose of this brief report is to evaluate safety and efficacy of bilateral Brolucizumab intravitreal injections in AMD patients.

#### **Methods:**

Four AMD patients treated bilaterally with Brolucizumab intravitreal injections were included in this brief report. All patients had a complete ophthalmological examination, including corrected visual acuity assessment, slit-lamp examination, intraocular pressure evaluation, fundus examination and OCT evaluation (Carl Zeiss Cirrus, model 5000). These appraisals were carried out one day before intravitreal injection and repeated the day after and one month later.

#### **Results:**

All included patients had three Brolucizumab intravitreal injections in each eye, alternating between the two eyes month by month. None of the patients showed ocular complications related to intravitreal treatment. All the patients had a visual acuity improvement of at least one optotype line for each treated eye, while no significant differences were found for intraocular pressure. At OCT evaluation, there was a significant decrease in intraretinal and subretinal fluid one month after the last injection.

#### **Conclusions:**

This brief report points out that bilateral treatment with Brolucizumab does not seem to present an increase in ocular adverse effects and shows a great improvement in the AMD edema. However, further studies are needed to confirm these results.